BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf 2014;6:145-9. [PMID: 25364275 DOI: 10.2147/DHPS.S68837] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Benjumea-Bedoya D, Becker M, Haworth-Brockman M, Balakumar S, Hiebert K, Lutz JA, Bertram Farough A, Keynan Y, Plourde P. Integrated Care for Latent Tuberculosis Infection (LTBI) at a Primary Health Care Facility for Refugees in Winnipeg, Canada: A Mixed-Methods Evaluation. Front Public Health 2019;7:57. [PMID: 30949466 DOI: 10.3389/fpubh.2019.00057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Masuka JT, Chipangura P, Nyambayo PP, Stergachis A, Khoza S. A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe. Clin Drug Investig 2018;38:9-17. [PMID: 28965312 DOI: 10.1007/s40261-017-0579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India. BMJ Glob Health 2018;3:e001135. [PMID: 30364389 DOI: 10.1136/bmjgh-2018-001135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Gomes J, Durães D, Sousa A, Afonso H. Isoniazid-Induced Acute Psychosis in a Patient with Pleural Tuberculosis. Case Rep Psychiatry 2019;2019:4272941. [PMID: 30906613 DOI: 10.1155/2019/4272941] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ghafouri SAR, Brun A, Bhalla R, Margulies C, Skole K. Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin. Case Rep Oncol Med 2018;2018:8280527. [PMID: 30245898 DOI: 10.1155/2018/8280527] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande MJ. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. BMC Infect Dis 2019;19:62. [PMID: 30654753 DOI: 10.1186/s12879-019-3696-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
7 Warstler A, Bean J. Antimicrobial-induced cognitive side effects. Ment Health Clin 2016;6:207-14. [PMID: 29955472 DOI: 10.9740/mhc.2016.07.207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
8 Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, White RA, Winje BA. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. BMC Infect Dis 2018;18:587. [PMID: 30453946 DOI: 10.1186/s12879-018-3468-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Thindwa D, MacPherson P, Choko AT, Khundi M, Sambakunsi R, Ngwira LG, Kalua T, Webb EL, Corbett EL. Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. Int J Tuberc Lung Dis 2018;22:273-9. [PMID: 29471904 DOI: 10.5588/ijtld.17.0370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
10 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
11 Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ding X, Ho CM, Horwitz MA. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun 2017;8:14183. [PMID: 28117835 DOI: 10.1038/ncomms14183] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
12 Ilievska-Poposka B, Metodieva M, Zakoska M, Vragoterova C, Trajkov D. Latent Tuberculosis Infection - Diagnosis and Treatment. Open Access Maced J Med Sci 2018;6:651-5. [PMID: 29731933 DOI: 10.3889/oamjms.2018.161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
13 Ragonnet R, Trauer JM, McBryde ES, Houben RM, Denholm JT, Handel A, Sumner T. Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. Int J Tuberc Lung Dis 2017;21:60-6. [PMID: 28157466 DOI: 10.5588/ijtld.16.0297] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Bangert MK, Hasbun R. Neurological and Psychiatric Adverse Effects of Antimicrobials. CNS Drugs 2019;33:727-53. [PMID: 31321707 DOI: 10.1007/s40263-019-00649-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]